Fulvestrant Market
This report contains market size and forecasts of Fulvestrant in global, including the following ... Read More
This report contains market size and forecasts of Endocrine Therapy Drugs for Breast Cancer in Global, including the following market information:
Global Endocrine Therapy Drugs for Breast Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Endocrine Therapy Drugs for Breast Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tamoxifen Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Endocrine Therapy Drugs for Breast Cancer include Teva, Amneal Pharms, AstraZeneca, Novartis, Intas Pharmaceuticals, Chemo, Accure Labs, Natco and Zydus Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Endocrine Therapy Drugs for Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Endocrine Therapy Drugs for Breast Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Endocrine Therapy Drugs for Breast Cancer Market Segment Percentages, by Type, 2021 (%)
Tamoxifen
Anastrozole
Exemestane
Letrozole
Goserelin
Fulvestrant
Global Endocrine Therapy Drugs for Breast Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Endocrine Therapy Drugs for Breast Cancer Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Drug Center
Other
Global Endocrine Therapy Drugs for Breast Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Endocrine Therapy Drugs for Breast Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Endocrine Therapy Drugs for Breast Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Endocrine Therapy Drugs for Breast Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva
Amneal Pharms
AstraZeneca
Novartis
Intas Pharmaceuticals
Chemo
Accure Labs
Natco
Zydus Pharmaceuticals
Sanofi
Pfizer
MylanÂ
Wockhardt
Cipla
Actiza Pharmaceutical
Hikma Pharmaceuticals
Shanghai Forward Technology
Bayer
Liaoning Kangtai Pharmaceutical
Fu 'an Pharmaceutical Group
Apotex
Taro
Sun Phamaceutical
Intas Pharmaceuticals
Chemo
Accure Labs
Sun Pharmaceutical
This report contains market size and forecasts of Fulvestrant in global, including the following ... Read More
This report contains market size and forecasts of Tubulin Inhibitors for Breast Cancer in Global, ... Read More
This report contains market size and forecasts of PARP Inhibitors for Breast Cancer in Global, in ... Read More
This report contains market size and forecasts of VEGF Targeted Drugs for Breast Cancer in Global ... Read More